EPO and myelodysplastic syndrome: Due to high TFR2 expression in erythroid lineage, and to its functional relationship with the erythropoietin receptor (EpoR) [68], TFR2 transcription was evaluated in patients with myelodysplastic syndromes (MDS), a hematopoietic disorder with a variable risk to evolve in acute myeloid leukemia (AML), and in which chronic anemia can be corrected by Epo injection [103].